MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561470 | Name: NSC156529
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NSC156529 downregulates AKT1 signaling, efficiently decreasing the proliferation of human cancer cells in vitro, and substantially inhibiting the growth of prostate tumor xenografts in vivo.

Chemical Structure

NSC156529
NSC156529
CAS#41134-88-7

Theoretical Analysis

MedKoo Cat#: 561470

Name: NSC156529

CAS#: 41134-88-7

Chemical Formula: C28H21ClS2

Exact Mass:

Molecular Weight: 457.05

Elemental Analysis: C, 73.58; H, 4.63; Cl, 7.76; S, 14.03

Price and Availability

Size Price Availability Quantity
5mg USD 250.00
25mg USD 650.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
NSC156529; NSC-156529; NSC 156529;
IUPAC/Chemical Name
6-Methyl-2-phenyl-10-phenylsulfanyl-1H-anthra[1,9-bc]thiophenium chloride
InChi Key
KLQVNXJBZZWIIV-UHFFFAOYSA-M
InChi Code
InChI=1S/C28H21S2.ClH/c1-19-22-14-8-16-25(29-20-10-4-2-5-11-20)27(22)24-18-30(21-12-6-3-7-13-21)26-17-9-15-23(19)28(24)26;/h2-17H,18H2,1H3;1H/q+1;/p-1
SMILES Code
CC1=C2C=CC=C(SC3=CC=CC=C3)C2=C4C5=C1C=CC=C5[S+](C6=CC=CC=C6)C4.[Cl-]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
NSC156529 downregulates AKT1 signaling.
In vitro activity:
The screen revealed one molecule-NSC156529, which downregulated AKT1 signaling, efficiently decreased the proliferation of human cancer cells in vitro, and substantially inhibited the growth of prostate tumor xenografts in vivo. Interestingly, the treated tumor xenografts exhibited higher expression level of normal prostate differentiation markers but did not show augmented cell death, suggesting that the identified compound primarily enhances the differentiation of malignant cells toward normal prostate epithelium and thus poses as an attractive lead compound for developing novel antitumor agents with less cytotoxic side effects. Reference: Mol Cancer Ther. 2015 Nov;14(11):2486-96. https://pubmed.ncbi.nlm.nih.gov/26294745/
In vivo activity:
The screen revealed one molecule-NSC156529, which downregulated AKT1 signaling, efficiently decreased the proliferation of human cancer cells in vitro, and substantially inhibited the growth of prostate tumor xenografts in vivo. Interestingly, the treated tumor xenografts exhibited higher expression level of normal prostate differentiation markers but did not show augmented cell death, suggesting that the identified compound primarily enhances the differentiation of malignant cells toward normal prostate epithelium and thus poses as an attractive lead compound for developing novel antitumor agents with less cytotoxic side effects. Reference: Mol Cancer Ther. 2015 Nov;14(11):2486-96. https://pubmed.ncbi.nlm.nih.gov/26294745/

Preparing Stock Solutions

The following data is based on the product molecular weight 457.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
Mäemets-Allas K, Viil J, Jaks V. A Novel Inhibitor of AKT1-PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo. Mol Cancer Ther. 2015 Nov;14(11):2486-96. doi: 10.1158/1535-7163.MCT-15-0281. Epub 2015 Aug 20. PMID: 26294745.
In vitro protocol:
Mäemets-Allas K, Viil J, Jaks V. A Novel Inhibitor of AKT1-PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo. Mol Cancer Ther. 2015 Nov;14(11):2486-96. doi: 10.1158/1535-7163.MCT-15-0281. Epub 2015 Aug 20. PMID: 26294745.
In vivo protocol:
Mäemets-Allas K, Viil J, Jaks V. A Novel Inhibitor of AKT1-PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo. Mol Cancer Ther. 2015 Nov;14(11):2486-96. doi: 10.1158/1535-7163.MCT-15-0281. Epub 2015 Aug 20. PMID: 26294745.
1: Mäemets-Allas K, Belitškin D, Jaks V. The inhibition of Akt-Pdpk1 interaction efficiently suppresses the growth of murine primary liver tumor cells. Biochem Biophys Res Commun. 2016 May 20;474(1):118-125. doi: 10.1016/j.bbrc.2016.04.082. Epub 2016 Apr 19. PubMed PMID: 27103434. 2: Mäemets-Allas K, Viil J, Jaks V. A Novel Inhibitor of AKT1-PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo. Mol Cancer Ther. 2015 Nov;14(11):2486-96. doi: 10.1158/1535-7163.MCT-15-0281. Epub 2015 Aug 20. PubMed PMID: 26294745.

View History

VT-107

VT-107

Featured